Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > April 29, Next Monday expecting an annual report, will see
View:
Post by managementfirst on Apr 24, 2024 10:46am

April 29, Next Monday expecting an annual report, will see

some update.
Comment by riverrrow on Apr 24, 2024 12:17pm
Something to look forward to.  GLTA.
Comment by Pandora on Apr 24, 2024 9:03pm
  Theralase 4,167,778-share private placement   2024-04-24 20:09 ET - Private Placement   The TSX Venture Exchange has accepted for filing documentation with respect to a non-brokered private placement announced on April 24, 2024.   Number of shares:  4,167,778 common shares Purchase price:  18 cents per common share Warrants:  4,167,778 common ...more  
Comment by menoalittle on Apr 25, 2024 12:31pm
If there were only 16 placees, seems quite low to me. Was anyone shut out that thought they were going to be in? And how many of those placees were insiders? Maybe they only took in as much money as they thought they needed to reach the next step? Hmmmm....
Comment by Alamir1111 on Apr 25, 2024 3:28pm
16 investors cought  up around 47 thousand $ average for 750 thou i think the minimum participation for pp  was 18 thou for accredited investors.Me thinking somebody is fool or smart?
Comment by Alamir1111 on Apr 25, 2024 3:40pm
AUG 2019 warrants expiring  2024.That's a huge nr  4 monts to go. Company issued 57,500,000 units of the Company (including the exercise in full of the over-allotment option) (the “Units”) at a price of $0.30 per Unit (the “Issue Price”) for gross proceeds of $17,250,000 (the “Offering”). Each Unit consisted of one common share of the Company (the “Common Shares”) and one ...more  
Comment by Alamir1111 on Apr 25, 2024 3:56pm
Ibrx in 2 days of trading after receiving btd gained  approximately 10%  $5.16 0.3399 |  7.05% Bid:  5.15 x 2,600 Ask:  5.16 x 500 Volume: 7,014,310 USD  |  NDAQ  |  DELAYED  |   |  APRIL 25, 2024 03:28:00 PM EDT
Comment by Alamir1111 on Apr 25, 2024 3:59pm
Somebody having a field day after the announced  pp Historical Short Volume Data for TLTFF Date Close High Low Volume Short Volume % of Vol Shorted Apr 24 NA NA NA 23,117 22,017 95.24
Comment by enriquesuave on Apr 25, 2024 6:07pm
  FDA approval was already baked in for IBRX, IMHO.  Market Cap is at $3.72 Billion USD.  100 times more than ours.  Like us being at 15-18$ US  
Comment by Alamir1111 on Apr 25, 2024 6:32pm
So nice you think btd is baked in at .16 for tlt. ?
Comment by Alamir1111 on Apr 25, 2024 6:45pm
https://stockhouse.com/news/press-releases/2024/04/25/immunitybio-announces-positive-overall-survival-results-of-anktiva-combined-with
Comment by Alamir1111 on Apr 25, 2024 6:49pm
Nice going for lung cancer preclinical research and development of Rutherrin®
Comment by CAinPlap on Apr 25, 2024 3:38pm
May I as respectfully as possible ask anyone thinking the company turned anyone's money away to please pull their head out of the sand.
Comment by Dumbeldorfwhite on Apr 25, 2024 4:11pm
Hahahaha don't tell the good ole boys club that, u might get sued!
Comment by Alamir1111 on Apr 25, 2024 6:29pm
Hi DDW or RDW whatever 17,250,000 $ somebody not going to be happy.Personal disclaimer I got no leg in that.
Comment by 2b7f6fab on Apr 25, 2024 7:01pm
Just drop the exercise price on all outstanding warrants to 15 cents, brings in $12 million.  Enough to finish the trial and begin others.  I bet share price would be back to pre covid levels very quickly. jmo
Comment by Alamir1111 on Apr 25, 2024 7:29pm
o you think this is a yard sale ?
Comment by Infinity on Apr 26, 2024 12:31pm
I like your idea.  I Don't think it is  Doable??.  
Comment by hilles on Apr 25, 2024 4:19pm
They accepted my money. I'm a drop of water in the lake. Hilles
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250